Celera and Ipsen to Develop Biomarkers, PGx Tests for Growth Failure Therapies | GenomeWeb
NEW YORK (GenomeWeb News) - Celera will help Ipsen develop pharmacogenomic tests that could be used in tandem with Ipsen’s hormone-replacement therapies for short stature, the companies said yesterday.
Under the first phase of the multi-year collaboration, Celera will work with the Paris-based specialty pharmaceutical company to locate and characterize genetic markers related to growth failure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.